Franklin Resources Inc. Increases Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Franklin Resources Inc. raised its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 83.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 66,461 shares of the biopharmaceutical company's stock after buying an additional 30,144 shares during the period. Franklin Resources Inc. owned about 0.12% of Agios Pharmaceuticals worth $2,184,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of AGIO. FMR LLC increased its stake in shares of Agios Pharmaceuticals by 283.2% in the 3rd quarter. FMR LLC now owns 45,393 shares of the biopharmaceutical company's stock valued at $2,017,000 after purchasing an additional 33,546 shares in the last quarter. State Street Corp increased its position in shares of Agios Pharmaceuticals by 10.2% in the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company's stock valued at $103,586,000 after buying an additional 216,484 shares in the last quarter. XTX Topco Ltd raised its stake in shares of Agios Pharmaceuticals by 56.2% during the 3rd quarter. XTX Topco Ltd now owns 8,329 shares of the biopharmaceutical company's stock worth $370,000 after buying an additional 2,996 shares during the period. Geode Capital Management LLC lifted its position in shares of Agios Pharmaceuticals by 0.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company's stock valued at $60,326,000 after buying an additional 6,101 shares in the last quarter. Finally, Exome Asset Management LLC purchased a new position in shares of Agios Pharmaceuticals during the 3rd quarter valued at approximately $2,941,000.

Remove Ads

Insider Activity

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of the company's stock in a transaction that occurred on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total value of $194,172.30. Following the transaction, the director now directly owns 149,220 shares in the company, valued at approximately $3,864,798. This represents a 4.78 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 4.93% of the company's stock.

Analyst Ratings Changes

Several research firms have issued reports on AGIO. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. StockNews.com cut Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, February 14th. Finally, HC Wainwright assumed coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They set a "buy" rating and a $58.00 target price for the company. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $56.57.

Agios Pharmaceuticals Price Performance

Agios Pharmaceuticals stock traded up $0.30 during trading on Tuesday, reaching $27.82. 607,625 shares of the company were exchanged, compared to its average volume of 710,601. The stock's 50 day simple moving average is $31.12 and its two-hundred day simple moving average is $38.98. The company has a market capitalization of $1.59 billion, a P/E ratio of 2.45 and a beta of 0.83. Agios Pharmaceuticals, Inc. has a 52-week low of $23.42 and a 52-week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. As a group, equities analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.